

Macular Degeneration

Treatment approaches covered

Intravitreal anti-VEGF treatment | Other intravitreal treatments | Photodynamic therapy | Thermal photocoagulation

Retinal radiation therapy | Transpupillary thermotherapy | Retinal surgical treatment



Details

- 1 Endophthalmitis
- 2 Individual treatments received for macular degeneration
- 3 Recommended to track via the Brief Impact of Vision Impairment (B_IVI) Questionnaire
- 4 Presence of fluid, edema, or hemorrhage

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit ichom.org/medical-conditions/Macular-Degeneration

Contributors

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit ichom.org/how-we-work/

The Sponsors



The Working Group



Australia

Mark Gillies | University of Sydney

India

Kim Ramasamy | Aravind Eye Care System

Japan

Nagahisa Yoshimura | Kyoto University
Hiroshi Tamura | Kyoto University

Malaysia

Norfariza Ngah | Hospital Selayang
Dato Shankar*

Netherlands

Caroline Klaver | Erasmus Medical Center

Singapore

Gemmy Cheung | Singapore National Eye Center

Sweden

Inger Westborg | Umeå University;
Registercenter Syd/EyeNet Sweden

Switzerland

Daniel Barthelmes | University Hospital Zurich

United Kingdom

Robert Johnston | Gloucestershire Hospitals NHS Foundation Trust
Adnan Tufail | Moorfields Eye Hospital
Ian Rodrigues | St. Thomas' Hospital
Martin McKibbin | Royal College of Ophthalmologists
Cathy Yelf* | Macular Society

United States

Mark Blumenkranz | The Byers Eye Institute at Stanford University

Suzann Pershing | Stanford University;
American Academy of Ophthalmology;
VA Palo Alto Health Care System

Christina Weng | Baylor College of Medicine

Julia Haller | Wills Eye Hospital; Thomas Jefferson University

*Patient representative